| Citation | Campbell is distinguished for his innovative and creative contributions to medicinal chemistry within the European and US pharmaceutical industry. He is the sole inventor on the patent which covers doxazosin, a novel alpha-adrenoceptor antagonist for the treatment of hypertension and benign prostatic hyperplasia This drug is marketed under the trade name Cardura ® and is widely accepted as "best in class" within its therapeutic group. World-wide sales of Cardura ® reached over $0.5 million in 1996. Campbell is also senior inventor on the patent which covers amplodipine, a novel calcium antagonist for the treatment of hypertension and angina. Marketed under Norvase ®, the drug is the leading calcium antagonist in world markets, with sales reaching $2.0 billion in 1997. During his leadership of Discovery Chemistry, and lately Discovery within Pfizer, a constant stream of innovative new agents have entered clinical evaluation. Campbell's innovation and creativity are recognised by leading academic institutes where he has had many long-standing and fruitful collaborations. In 1989, he received the Royal Society of Chemistry Medal for Medicinal Chemistry, and in 1997 the E B Hershberg Award from the American Chemical Society for "important discoveries in medicinally active substances". He was also awarded the 1997 Achievement Award from the Industrial Research Institute (IR), the pre-eminent organisation of research management in the U.S. Campbell is a are example of a research scientist who has been directly involved in the discovery of two hugely successful commercial drugs, which have made him widely regarded as a leading medicinal chemist in the world. |